Drug
sofosbuvir and daclatasvir
sofosbuvir and daclatasvir is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
20%
Ph early_phase_1
1
20%
Ph phase_4
1
20%
Ph phase_3
2
40%
Phase Distribution
1
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Other(1)
Detailed Status
Completed4
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
Trials by Status
completed480%
unknown120%
Recent Activity
0 active trials
Showing 5 of 5
unknownearly_phase_1
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
NCT03882307
completedphase_2
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
NCT02555943
completedphase_3
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
NCT03369327
completedphase_4
Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients
NCT03200184
completedphase_3
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
NCT02576314
Clinical Trials (5)
Showing 5 of 5 trials
NCT03882307Early Phase 1
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
NCT02555943Phase 2
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
NCT03369327Phase 3
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
NCT03200184Phase 4
Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients
NCT02576314Phase 3
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5